...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery
【24h】

Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery

机译:用新辅助化疗治疗食管鳞状细胞癌的肿瘤反应,然后进行手术治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aim: Neoadjuvant therapy followed by surgery is the standard treatment for advanced esophageal cancer. This study aimed to evaluated the potential of F-18-fluorodeoxyglucose positron-emission tomography to predict the pathological therapeutic effect of neoadjuvant chemotherapy. Patients and Methods: We enrolled 68 patients with advanced esophageal squamous cell carcinoma who underwent F-18-fluorodeoxyglucose positron-emission tomography before and after neoadjuvant chemotherapy, followed by surgery. Retrospective analysis of the pathological therapeutic effects was performed. Results: The pathological therapeutic effect of good responders was significantly inversely associated with the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy and with SUVmax reduction (both p<0.0001). Univariate and multivariate analyses revealed that lower post therapy SUVmax and reduction in SUVmax were independent prognostic factors for relapse-free (p=0.02) and overall survival (p<0.0001). Conclusion: Post-neoadjuvant chemotherapy SUVmax and SUVmax reduction can predict the pathological therapeutic effect of neoadjuvant chemotherapy.
机译:背景/目的:新辅助治疗随后进行手术是前进食管癌的标准治疗方法。本研究旨在评估F-18-氟脱氧葡萄糖正电子排放断层扫描的潜力,以预测Neoadjuvant化疗的病理治疗效果。患者和方法:我们注册了68例治疗前后氟脱氧葡萄糖正电子排放断层扫描的68例患有先进的食管鳞状细胞癌,在新辅助化疗之前和之后,然后进行手术。进行了对病理治疗效果的回顾性分析。结果:良性响应者的病理治疗效果与新辅助化疗后最大标准化摄取值(SUVMAX)与Suvmax降低(P <0.0001)的最大标准化摄取值(Suvmax)相关。单变量和多变量分析显示,降低的后治疗Suvmax和Suvmax的还原是无休止的复发(P = 0.02)和总存活的预后因素(P <0.0001)。结论:新辅助化疗Suvmax和Suvmax降低可预测Neoadjuvant化疗的病理治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号